GLP-1 receptor agonists, particularly semaglutide and tirzepatide, have fundamentally changed how patients and prescribers approach metabolic health and weight management. As demand has grown, so has the need for a reliable compounding pharmacy for semaglutide and tirzepatide that can meet highly individualized patient needs. Standardized commercial formats cannot accommodate the full spectrum of how prescribers and patients now use these therapies.
The commercial shortage period also revealed something important. Many patients had no idea that licensed, regulated compounding pharmacies existed as a legitimate alternative. The shortage has since been officially resolved, but what it exposed remains relevant. There is a significant gap between what commercial medications offer and what patients with individualized needs actually require, and that is precisely the gap compounding pharmacies exist to fill.
For prescribers seeking custom dosing solutions, including microdosing tirzepatide and microdosing semaglutide protocols, the pharmacy they choose matters enormously. As clinical experience with these medications grows, compounding pharmacies are increasingly stepping in to meet needs commercial products cannot address.
What Is GLP-1 Microdosing, and Why Do Patients Need a Compounding Pharmacy?
GLP-1 receptor agonists like semaglutide and tirzepatide are commercially available in fixed pre-filled pens and certain multidose formats. Those options work well for many patients. But clinical practice has quickly shown that a meaningful subset of patients does not fit neatly into the standard protocol, and prescribers often have clinical reasons to go beyond what any commercial format can offer:
-
Patients highly sensitive to GI side effects such as nausea who need a slower, more precise titration than any fixed-dose schedule allows.
-
Patients who have reached their therapeutic goals and need a maintenance dose not available in a commercial format.
-
Patients pursuing microdosing, where sub-standard doses are titrated to individual tolerance and response. In early 2025, researchers at the University of North Carolina published a letter in Diabetes Care formally defining this practice.
-
Experienced patients working with their prescriber on split dosing, dividing a weekly dose across two or three injections to smooth peaks and troughs and better match their daily routine.
-
Patients who adjust dosing around life events under prescriber guidance, then return to baseline. As patients become more experienced with how their body responds to GLP-1 therapy, this kind of dynamic, prescriber-guided self-management is becoming more common.
-
Patients benefiting from targeted additives a compounding pharmacy can incorporate, such as leucine to help support lean muscle preservation, methylcobalamin (B12) and pyridoxine (B6) for neurological and metabolic support, or L-carnitine for energy metabolism. None of these combinations are available in any commercial GLP-1 formulation.
Commercial GLP-1 products come in fixed formats — which may work for many patients, but leaves gaps for those who need dose flexibility, individualized titration, or specific therapeutic additives. The key point for prescribers is this: truly individualized GLP-1 therapy, whether that means microdosing, split dosing, lifestyle-responsive adjustments, or custom formulations with additives, requires a sterile compounding pharmacy capable of preparing precise, patient-specific injectable formulations under the highest standards of quality and safety.
Are your GLP-1 patients asking for more flexibility in their dosing? Partner with Town and Country Compounding to discuss custom formulation options for your practice.
What Separates a True Sterile Compounding Pharmacy
When it comes to injectable medications like semaglutide and tirzepatide, the difference between a properly accredited sterile compounder and a substandard operation is the difference between a safe, precisely dosed medication and a potentially dangerous one.
This matters especially for prescribers operating in, or referring patients to, med spas, weight-loss clinics, and medical offices that prepare or handle injectable GLP-1 medications on-site. Enthusiasm around these therapies has outpaced awareness of what is and is not compliant in sterile preparation, and that gap creates real patient-safety risk.
There is an important line between administering a commercially prepared injectable and preparing or reconstituting one on-site. The latter enters the territory of sterile compounding, which carries distinct regulatory requirements a standard clinical environment is not designed to meet. A treatment room does not have the environmental controls, air handling, or continuous monitoring of an ISO-classified cleanroom. Preparing injectables outside a USP 797-compliant facility introduces contamination risk patients cannot see, including bacterial, fungal, and particulate contamination that can cause injection-site infections, systemic infections, and in severe cases sepsis. These are documented outcomes, not hypotheticals. Sourcing of raw materials and active ingredients from unverified suppliers introduces further unknowns around purity and potency.
Here is what prescribers should require from any pharmacy preparing injectable GLP-1 formulations for their patients:
-
USP 797 sterile compounding compliance. USP Chapter 797 sets the enforceable standards for sterile preparations, covering facility design, environmental monitoring, beyond-use dating, and personnel training. These are legally enforceable requirements, not guidelines.
-
ISO-classified cleanrooms. Sterile injectables must be prepared in ISO-classified environments, with positive-pressure rooms for non-hazardous sterile preparations and negative-pressure rooms for hazardous materials, continuously monitored for particulates, microbial contamination, temperature, and pressure.
-
PCAB, ACHC, and NABP accreditation. These designations require independent, rigorous review of a pharmacy's processes, quality systems, personnel, and facilities. They are earned, not purchased, and are held by only a small percentage of U.S. compounding pharmacies.
-
Independent quality testing. Active ingredients sourced from FDA-inspected facilities, plus independent potency and sterility testing on finished preparations, provide assurance no office-based reconstitution can match.
Not sure if your current compounding pharmacy meets these standards? Watch how Town and Country Compounding prepares sterile medications and see the difference accreditation makes.
Town and Country Compounding: Sterile Standards That Go Above and Beyond
Town and Country Compounding, based in Ramsey, New Jersey, is a PCAB-, ACHC-, and NABP-accredited 503A compounding pharmacy serving patients and prescribers across more than 22 states. For prescribers seeking a compounding pharmacy for semaglutide or tirzepatide custom dosing, Town & Country Compounding brings the sterile infrastructure, accreditation, and clinical collaboration to do it right.
What sets Town and Country apart:
-
Multiple ISO-classified cleanrooms with separate positive- and negative-pressure environments
-
Full USP 797 sterile compounding compliance on every preparation
-
Active ingredients sourced exclusively from FDA-inspected facilities
-
Independent potency and sterility testing on finished preparations
-
PCAB, ACHC, and NABP accreditation, earned through independent review, not self-reported
-
Custom GLP-1 formulations, including microdosing, split dosing, and additive-enhanced preparations, compounded to each patient's specific, prescriber-directed needs
-
Direct prescriber collaboration through a dedicated prescriber portal
Ready to set up your practice with a trusted sterile compounding partner? Access the Prescriber Portal or contact our team to get started.
What Prescribers Are Saying
Town and Country has earned consistent 5-star reviews from practitioners across specialties.
"Patients do better when they get their medicine from Town and Country Compounding. They have invested in quality assurance. That is what you are paying for. I rely on Town and Country as our go-to compounding pharmacy." Dr. AnnaLisa Pastore, MD, Center for Holistic and Integrative Medicine, Harrington Park, NJ.
Individual experiences and clinical outcomes vary. Testimonials do not constitute a guarantee of results.
Clinical Necessity Is Required for Compounded GLP-1 Prescriptions
Under current 503A regulations, a compounding pharmacy may only prepare semaglutide or tirzepatide formulations that represent a clinically significant difference from the commercially available product. Prescribers must document a specific, patient-level clinical rationale on every prescription. Compounding at standard doses without a documented distinction is not legally defensible under current FDA guidance.
Accepted reasons for clinical necessity include:
-
Intolerance to GI side effects requires a low-dose titration schedule not available commercially
-
Need for split dosing across two or three weekly injections at doses not available commercially
-
Allergy or sensitivity to an inactive ingredient in the commercial formulation, such as benzyl alcohol, excipients, or preservatives
-
Requirement for a preservative-free formulation
-
Therapeutic-additive requirements, such as leucine, methylcobalamin (B12), pyridoxine (B6), or L-carnitine
-
A specific dose strength or concentration not available in any commercial format
-
An alternative delivery method or dosage form not available commercially
The clinical necessity must be explicitly documented on the prescription by the ordering prescriber. Town & Country Compounding works closely with prescribers to ensure every compounded GLP-1 formulation is supported by appropriate documentation. Questions about clinical-necessity documentation? Contact our pharmacist team.
A Note on the Evolving Regulatory Landscape
The regulatory environment for compounded GLP-1 medications has tightened significantly since the shortage period ended. Large-scale commercial compounding of semaglutide and tirzepatide has been restricted, and the FDA has pursued enforcement actions against operations outside compliant compounding frameworks.
Legitimate compounding under 503A, by state-licensed pharmacies filling patient-specific prescriptions with a documented clinical rationale, continues as a pathway for patients with genuine individualized needs. The standard of pharmacy practice matters more than ever. Town & Country Compounding's PCAB, ACHC, and NABP accreditation, ISO-classified sterile labs, and quality commitment make it a partner prescribers can trust when patients need something the commercial market cannot provide.
Frequently Asked Questions
What is microdosing tirzepatide?
Microdosing tirzepatide refers to using sub-standard doses of tirzepatide, titrated to an individual patient's tolerance and response under prescriber direction. Because commercial pens come in fixed doses, microdosing protocols generally require a patient-specific compounded formulation prepared by a sterile, USP 797-compliant compounding pharmacy, supported by a documented clinical rationale.
What is the difference between microdosing and split dosing GLP-1 medications?
Microdosing uses lower-than-standard doses titrated to individual response. Split dosing divides a weekly dose across two or three injections to smooth peaks and troughs and improve consistency. Both are prescriber-directed strategies, and both typically require custom-compounded, patient-specific formulations not available in commercial formats.
Can a compounding pharmacy prepare custom-dose semaglutide or tirzepatide?
Yes. Under 503A, a state-licensed compounding pharmacy can prepare patient-specific semaglutide or tirzepatide formulations when a prescriber documents a clinically significant difference from the commercial product, for example an intolerance-driven microdose titration or a preservative-free formulation. It must be prepared under USP 797 sterile standards and dispensed only with a valid prescription.
What should prescribers look for in a compounding pharmacy for GLP-1 medications?
USP 797 sterile compliance, ISO-classified cleanrooms, PCAB, ACHC, and NABP accreditation, active ingredients from FDA-inspected suppliers, and independent potency and sterility testing on finished preparations.
Is compounded GLP-1 therapy still legal now that the shortage has ended?
Patient-specific compounding under 503A remains a legal pathway when a prescriber documents clinical necessity. Large-scale commercial copying of these drugs has been restricted. Prescribers should confirm current formulary availability and compliance status with the pharmacy directly.
For Prescribers: Partner With a Pharmacy That Earns Your Trust
If you are managing patients on GLP-1 therapy, whether initiating treatment, managing side effects through individualized titration, or supporting long-term metabolic goals, you deserve a compounding partner with the precision, safety, and flexibility only an accredited sterile compounder can provide.
Town and Country Compounding offers:
-
Sterile compounding under full USP 797 compliance
-
ISO-classified cleanroom facilities
-
PCAB, ACHC, and NABP accreditation
-
Active ingredients from FDA-inspected facilities with independent testing
-
A prescriber portal for seamless collaboration and refills
-
Shipping to more than 22 states
Access the Prescriber Portal, partner with us, or watch the sterile compounding video.
This article is intended for licensed prescribers and healthcare professionals. Compounded medications are not FDA-approved finished drug products. All prescribing decisions, including custom dosing and titration protocols, must be made by a licensed clinician based on individual patient clinical need. Town and Country Compounding compounds patient-specific formulations in compliance with applicable state and federal regulations.
